Antibiotic resistance: the challenge from an industry perspective

Area of Science:

• Medical Microbiology
• Infectious Diseases
• Pharmaceutical Industry

Background:

• Glenn Tillotson possesses over 20 years of pharmaceutical experience, specializing in anti-infectives.
• His expertise spans clinical research, marketing, strategic development, and global drug launch programs.
• Tillotson has been involved in the development of key antibiotics like ciprofloxacin and moxifloxacin.

Purpose of the Study:

• To provide an industry perspective on the challenge of antibiotic resistance.
• To highlight the complexities of drug development and commercialization in the anti-infective field.
• To share insights from a seasoned pharmaceutical professional on addressing antimicrobial resistance.

Main Methods:

• Expert interview format.
• Discussion based on extensive industry experience in anti-infective drug development and launch.
• Focus on the challenges faced by the pharmaceutical industry in combating antibiotic resistance.

Main Results:

• The discussion underscores the multifaceted nature of antibiotic resistance as a critical global health issue.
• It highlights the significant role of the pharmaceutical industry in developing new anti-infective agents.
• Insights are provided on the strategic and commercial aspects of bringing new antibiotics to market.

Conclusions:

• Combating antibiotic resistance requires a concerted effort from various stakeholders, including the pharmaceutical industry.
• Continued innovation and strategic development are crucial for addressing the growing threat of antimicrobial resistance.
• The industry perspective offers valuable insights into the practical challenges and opportunities in the fight against resistant infections.